Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction

AIMS: Concomitant renin–angiotensin–aldosterone system blockade and natriuretic peptide system enhancement may provide unique therapeutic benefits to patients with heart failure and reduced ejection fraction (HFrEF). This study assessed the pharmacodynamics and pharmacokinetics of LCZ696 in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobalava, Zhanna, Kotovskaya, Yulia, Averkov, Oleg, Pavlikova, Elena, Moiseev, Valentine, Albrecht, Diego, Chandra, Priya, Ayalasomayajula, Surya, Prescott, Margaret F., Pal, Parasar, Langenickel, Thomas H., Jordaan, Pierre, Rajman, Iris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108443/
https://www.ncbi.nlm.nih.gov/pubmed/26990595
http://dx.doi.org/10.1111/1755-5922.12183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108443/
https://www.ncbi.nlm.nih.gov/pubmed/26990595
http://dx.doi.org/10.1111/1755-5922.12183

Ejemplares similares